In the last trading session, 5.35 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.18. Most recently the company’s share price was $0.62, and it changed around -$0.01 or -0.51% from the last close, which brings the market valuation of the company to $159.39M. ADAP currently trades at a discount to its 52-week high of $2.05, offering almost -230.65% off that amount. The share price’s 52-week low was $0.43, which indicates that the current value has risen by an impressive 30.65% since then. We note from Adaptimmune Therapeutics Plc ADR’s average daily trading volume that its 10-day average is 1.74 million shares, with the 3-month average coming to 1.57 million.
Adaptimmune Therapeutics Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.89. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended ADAP as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Instantly ADAP has showed a red trend with a performance of -0.51% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.7350 on recent trading dayincreased the stock’s daily price by 15.65%. The company’s shares are currently down -21.45% year-to-date, but still down -10.81% over the last five days. On the other hand, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is -21.83% down in the 30-day period. We can see from the shorts that 5.35 million shares have been sold at a short interest cover period of 4.71 day(s).
The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 84.5% from its current value. Analyst projections state that ADAP is forecast to be at a low of $4 and a high of $4.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Adaptimmune Therapeutics Plc ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -40.11 percent over the past six months and at a 77.78% annual growth rate that is well above the industry average of 17.10%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.30%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR’s next quarterly earnings report is expected to be released in January.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.38% of Adaptimmune Therapeutics Plc ADR shares, and 60.27% of them are in the hands of institutional investors. The stock currently has a share float of 60.49%. Adaptimmune Therapeutics Plc ADR stock is held by 95.0 institutions, with MATRIX CAPITAL MANAGEMENT COMPANY, LP being the largest institutional investor. By 2024-06-30, it held 16.1135% of the shares, which is about 38.97 million shares worth $38.0 million.
ECOR1 CAPITAL, LLC, with 11.3299% or 27.4 million shares worth $26.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
